RespireRx Pharmaceuticals (RSPI) News Today $0.0008 0.00 (-60.00%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Headlines Stock AnalysisChartFinancialsSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord InjuryMay 29, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc (RSPI)May 23, 2024 | investing.comRespireRx Pharmaceuticals Inc RSPIMay 1, 2024 | morningstar.comRCKT Rocket Pharmaceuticals, Inc.April 20, 2024 | seekingalpha.comRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord InjuryMarch 20, 2024 | globenewswire.comRespireRx Pharmaceuticals shares Preclinical Pain Relief for their Non-Opioid Lead KRM-II-81March 9, 2024 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsJanuary 22, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic PatientJanuary 4, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business DevelopmentDecember 11, 2023 | finance.yahoo.comRespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturingOctober 12, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related ServicesOctober 12, 2023 | finance.yahoo.comPharmaceutical cannabis sales surge, clinical trials seeing broader disease focusAugust 30, 2023 | proactiveinvestors.comRespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRxAugust 9, 2023 | benzinga.comRespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating CompanyAugust 9, 2023 | finance.yahoo.comAlnylam Pharmaceuticals (NASDAQ: ALNY)June 24, 2023 | fool.comRespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investmentMay 24, 2023 | proactiveinvestors.comResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development CostsMay 24, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. (RSPI)May 16, 2023 | finance.yahoo.comRespireRx collaborates with University College London to study treatment options for GRIA disordersApril 21, 2023 | finance.yahoo.comRespireRx collaborating with University College London to study treatment options for GRIA disordersApril 20, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA DisordersApril 5, 2023 | finance.yahoo.comRespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publicationsApril 3, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.April 3, 2023 | finance.yahoo.comRespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its boardMarch 28, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of DirectorsMarch 28, 2023 | finance.yahoo.comRSPI RespireRx Pharmaceuticals Inc.March 21, 2023 | seekingalpha.comRespireRx Pharmaceuticals subsidiary ResolutionRX signs on iNGENu as CRO for dronabinol developmentMarch 2, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australian subsidiary ResolutionRx enters services agreement with CRO iNGENuMarch 1, 2023 | proactiveinvestors.comResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty LtdMarch 1, 2023 | finance.yahoo.comResolutionRx announces research & development financing agreement with Radium CapitalFebruary 9, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australian subsidiary inks loan agreements to advance R&D for sleep apnea treatmentFebruary 1, 2023 | proactiveinvestors.comResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development CreditsFebruary 1, 2023 | finance.yahoo.comRespireRx Pharmaceuticals strikes second amendment to its license agreement with the University of IllinoisJanuary 23, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals establishes ResolutionRx subsidiary in AustraliaJanuary 23, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of IllinoisJanuary 23, 2023 | finance.yahoo.comRespireRX Pharmaceuticals establishes ResolutionRX in Australia to advance its cannabinoid programJanuary 12, 2023 | proactiveinvestors.comRespireRx sets up new Australian company to develop cannabinoid platformJanuary 12, 2023 | seekingalpha.comRespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid PlatformJanuary 12, 2023 | finance.yahoo.comRespireRx Pharmaceuticals joins NIH program to find non-opioid pain-relief mechanisms to combat addictionDecember 5, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical DevelopmentDecember 5, 2022 | finance.yahoo.comRespireRx Pharmaceuticals shares new letter of intent with Australian companyNovember 28, 2022 | proactiveinvestors.comRespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep ApneaNovember 17, 2022 | benzinga.comRespireRx Pharmaceuticals signs letter of intent with Australian CRO to study drug for treating obstructive sleep apneaNovember 17, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep ApneaNovember 17, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4November 10, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery SummitNovember 7, 2022 | finance.yahoo.comCANbridge Pharmaceuticals Data on CAN106 to be Presented at Two ConferencesSeptember 25, 2022 | finance.yahoo.comRespireRx Pharmaceuticals says its obstructive sleep apnea drug dronabinol featured in Sleep Review magazine free e-bookAugust 8, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 EditionAugust 8, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals SummitMay 24, 2022 | finance.yahoo.com Get RespireRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RSPI and its competitors with MarketBeat's FREE daily newsletter. Email Address ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price. Click here for the ticker >>> RSPI Media Mentions By Week RSPI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RSPI News Sentiment▼0.000.60▲Average Medical News Sentiment RSPI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RSPI Articles This Week▼00▲RSPI Articles Average Week Get RespireRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RSPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PPBT News CANF News ELAB News ULUR News BNOX News CPMD News ORGS News ADTX News ALZN News ALLR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RSPI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RespireRx Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RespireRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
